Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Illinois: - Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Illinois: - Hope and Healing Cancer Services — Hinsdale, Illinois
- Advocate Lutheran General Hospital — Park Ridge, Illinois
- Illinois CancerCare — Peoria, Illinois
Phase 3 Recruiting Industry
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease p…
Sponsor: Replimune, Inc.
NCT ID: NCT06264180
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
- Advocate Lutheran General Hospital — Park Ridge, Illinois
Phase 3 Recruiting Industry
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a …
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06585410
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
- Oak Dermatology — Naperville, Illinois
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Sites in Illinois: - Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI — Chicago, Illinois
Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in Illinois: - University of Illinois at Chicago — Chicago, Illinois
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with im…
Sponsor: Replimune, Inc.
NCT ID: NCT06581406
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Sites in Illinois: - University of Illinois Hospital & Health Sciences System — Chicago, Illinois
Phase 3 Recruiting Industry
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …
Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Illinois: - Saint Anthony's Health — Alton, Illinois
- Rush - Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Memorial Hospital of Carbondale — Carbondale, Illinois
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Illinois: - Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
Phase 2 Recruiting NIH
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in Illinois: - Rush-Copley Medical Center — Aurora, Illinois
- Centralia Oncology Clinic — Centralia, Illinois
- Northwestern University — Chicago, Illinois
- Carle at The Riverfront — Danville, Illinois
- Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Memorial Hospital East — Shiloh, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois: - Orchard Healthcare Research Inc. — Skokie, Illinois
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Illinois: - University of Illinois Cancer Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Sponsor: Immatics US, Inc.
NCT ID: NCT03686124
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06413680
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test th…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06121180
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Illinois: - Illinois Cancer Specialists — Arlington Heights, Illinois
- University of Illinois — Chicago, Illinois
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05107674
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1 Recruiting Industry
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-…
Sponsor: Y-mAbs Therapeutics
NCT ID: NCT05130255
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1 Recruiting Academic/Other
Nivolumab (and other agents affecting the anti-programmed death-1 \[anti-PD-1\] pathway) have demonstrated anti-tumor activity in multiple tumor types. Combinations of immune-oncology (IO) agents with complimentary mechanisms as well as ra…
Sponsor: Yana Najjar
NCT ID: NCT04572451
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 1 Recruiting Academic/Other
Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced me…
Sponsor: Loyola University
NCT ID: NCT02870244
Sites in Illinois: - Loyola University Medical Center — Maywood, Illinois